Complication, patency and incidence rates of first-time vascular dialysis access fashioned in Malta by Gatt, Thomas et al.
  
The Editorial Board retains the copyright of all material published in the Malta Medical School Gazette. Any reprint in any form of any 
part will require permission from the Editorial Board. Material submitted to the Editorial Board will not be returned, unless specifically 
requested. 
Malta Medical School Gazette      Volume 04 Issue 01 2020           
ORIGINAL ARTICLE 
Complication, patency and incidence rates of first-time 
vascular dialysis access fashioned in Malta 
 
Thomas Gatt, Adriana Grech, Kevin Cassar                            
BACKGROUND 
The aim of the study was to assess first-time arteriovenous fistulae 
(AVFs) and grafts fashioned over a 5 year period in Malta, and analyse 
their patency and complication rates. The study also investigates 
compliance with Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines for fistula incidence.  
METHODS 
Patients who underwent surgery between January 1st 2012 and 
December 31st 2016 were identified through the vascular surgery 
database at Mater Dei Hospital - Malta and followed up until 31st 
December 2017. Complications, interventions and patency duration 
were recorded from patient notes. Patency rates were calculated 
with Kaplan-Meier curves and log-rank test was used to compare 
significance between the curves.  
RESULTS 
A total of 258 vascular access (VA) procedures were analysed, only 
242 of which were used for haemodialysis. The chance of a VA 
developing no complications was 38%, with stenosis and thrombosis 
rates of 36.8% and 24.8% respectively. There was no significant 
difference between the complication rates or intervention frequency 
when comparing different fistula types. Of the 207 patients who had 
AVFs created since January 2012, only 26.1% (n=54) had creation 
prior to initiation of haemodialysis. Primary patency survival rates for 
first-time AVFs were 58.7±7.1% at 1 year and 48.1±7.4% at 2 years. 
The assisted primary rates were 73.7±6.3% at 1 year and 67.6±6.9% 
at 2 years. The secondary patency rates were 76.4±6.1% (95% CI, 
70.3%-82.5%) at 1 year and 70.8 ±6.9% at 2 years. There was no 
significant difference when comparing primary (p=0.539), assisted 
primary (p=0.634) or secondary patency (p=0.783) rates for the 
different AVF types.  
CONCLUSION:  
In Malta, AVF incidence lags behind the European average of 66%, 
but patency rates compare favorably with most other countries. 
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INTRODUCTION  
The number of patients receiving renal dialysis 
is steadily increasing, particularly in countries 
like Malta with a high prevalence of diabetes 
mellitus. Renal guidelines recommend the use 
of longer and more frequent haemodialysis 
(HD) sessions for which vascular access is 
required.1 The aim of this study is to assess 
first-time arteriovenous fistulae (AVFs) and 
arteriovenous grafts (AVGs) fashioned over a 5 
year period in Malta, and analyse their patency 
and complication rates. The study also 
investigates the time of fistula creation 
relative to haemodialysis start date, and 
compliance with Kidney Disease Outcomes 
Quality Initiative (KDOQI) guidelines with 
regard to fistula incidence.2 
 
MATERIALS AND METHODS 
Data Collection 
All patients undergoing AVF or AVG creation 
surgery between January 1st 2012 and 
December 31st 2016 were identified through 
the vascular surgery database at Mater Dei 
Hospital, Malta. This hospital is the only centre 
in Malta were vascular access is fashioned 
surgically and is thus representative of the 
entire Maltese population.  Vascular access 
procedures are performed by one vascular 
surgeon in Malta. 
The vascular surgery history of this cohort was 
followed up until 31st December 2017.   
Complications, interventions and patency 
rates for all fistulae were recorded.  For 
patients who passed away during the study 
period, records were reviewed till the date of 
death. 
 
Data on patient age and gender, the type and 
site of fistula created, the date when created, 
number of days of patency, types of 
complications, types of interventions required, 
date of HD initiation and the date of death 
were collected.  
Data for time of HD initiation was collected 
from records kept by the Mater Dei Hospital 
Renal Unit. The only digital records found 
available had only started being kept from 
January 2013 onwards. For earlier data, HD 
start date was taken as the date the patient 
was first registered to the renal unit on iSoft 
Clinical Manager.  Dates from both sources 
were cross checked for accuracy.  
Only patients above 18 years, who had a first-
time AV fistula or graft created locally 
between the data collection period, were 
included in this study.  Patients whose VA was 
not used for hemodialysis, were included in 
analysis of the fistula types created, however 
excluded from analysis of the complication 
and patency rates. This was done to eliminate 
bias from unused accesses.  
Definitions 
Definitions of vascular terms were as per 
standardized definitions by Lee et al. 3 The 
term vascular access (VA) was used to define 
any AVF or AVG. When referring to AVFs, we 
were including brachiocephalic, radiocephalic, 
ulnarcephalic, snuffbox and transposed 
brachiobasilic, ulnar basilica and radiobasilic 
fistulae.  AVGs were defined as any artificial 
prosthetic segment used to contact the artery 
and vein. 3 
Complications were classified as thrombosis, 
stenosis, complete occlusion, infection, steal 
syndrome, aneurysmal dilation and non-
maturation.3 Only complications documented 
in the patient’s notes were recognized. In 
some cases a fistula or graft may have 
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developed a recurrence of the complication 
after it was initially treated, and in other cases, 
more than one complication may have co-
existed.  
The interventions carried out on a VA were 
classified as angioplasty, thrombectomy and 
any surgical revision of the fistula or graft. 
Again, many repeat interventions may have 
been carried out on the same fistula or graft.3 
Patency was defined as described by Sidawy et 
al.4 Primary patency was defined as time of 
access placement to the time of first 
angioplasty.  Assisted primary patency was 
defined as time of access to the time of first 
thrombectomy. Secondary patency was 
defined as the time of access placement to 
access abandonment. Fistula incidence rates 
refer to the amount of people starting dialysis 
with a functioning fistula. Survival rates refer 
to the amount of fistulas which maintained 
their patency. 
StatisticsIBM SPSS Statistics 20.0 software was 
used to analyse the collected data. 
Comparison between categorical variables 
was with the chi-squared test. Patency rates 
were calculated with survival analysis curves 
(Kaplan Meir curves), and log-rank test was 
used to compare significance between the 
curves. A p value of ≤0.05 was considered 
statically significant in all cases. 
RESULTS 
The sample assessed included a total of 258 
patients, 70.2% (n=181) of which were male, 
while 29.8% (n=77) were female. The mean 
patient age at the time of fistula creation was 
63 years (SD=12.7).  
The different types of VA created are shown in 
Table 1. The most common VA type was 
brachiocephalic, accounting for 53.1% (n=137) 
of VAs. Radiocephalic (n=41), prosthetic grafts 
(n=35), transposed (n=27) and snuffbox (n=12), 
and ulnar cephalic (n=6) accounted for the rest. 
A total of 162 fistulas were sited on the left, 
while 96 were sited on the right. 
 
Table 1 Types of arteriovenous vascular access created 
 Number (%) 
Total 258  (100) 
Brachiocephalic 137  (53.1) 
Radiocephalic 41  (15.9) 
At the wrist 28  (10.9) 
At the forearm 13  (5.1) 
Prosthetic graft 35  (13.6) 
Arm Loop 33  (12.8) 
Ulnar Artery to Axillary Vein   1  (0.4) 
External Iliac to Profunda 
Vein 
1  (0.4) 
Snuffbox 12  (4.7) 
Transposed 27  (10.5) 
Brachiobasilic 24  (9.3) 
Ulnarbasilic 1  (0.4) 
Radiobasilic 2  (0.8) 
Ulnarcephalic 6  (2.3) 
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In cases were a prosthetic graft was fashioned, 
polytetrafluoroethylene (PTFE) was used in all 
cases. The majority of these grafts (12.8%, 
n=33) were arm loop fistulas. 
Patient Outcome 
Of the 258 patients assessed for VA creation in 
the 5 year period, a total of 121 patients had 
died before the 31st December 2017 cut off.   
Mean number of days between date of fistula 
creation and death was 510 days.  
The majority of patients (82.9%, n=214) 
remained dialyzing until death or until the cut 
off period. The rest were either transplanted 
successfully (8.1%, n=21), found to not require 
haemodialysis despite fistula creation (6.2%, 
n=16), stopped renal replacement therapy 
completely (1.6%, n=4) or reverted to 
peritoneal dialysis (0.8%, n=2). One person had 
left the country and was thus lost to follow-up.  
Complications 
The breakdown of the different complications 
and their frequency, after excluding the 16 
VAs which were never used for haemodialysis, 
are shown in Table 2. The chance of a VA not 
developing any complications was 38%, whilst 
the chances of stenosis or thrombosis at least 
once where 36.8% and 24.8% respectively.  
With regard to recurrent complications, the 
total number of stenotic events and 
thrombotic events were 138 and 102 
respectively for 242 VAs.  
 
 
Table 2 Complication Rates 
 Number (%) 
Total VAs 1 242 (100) 
     No Complications 91 (37.6) 
     Stenosis   89 (36.8) 
     Thrombosis  60 (24.8) 
     Occlusion  30 (12.4) 
     Aneurysm 27 (11.2) 
     Steal Syndrome 16 (6.6) 
     Infection 6 (2.5) 
     Non-maturation 4 (1.7) 
     Rupture 3 (1.2) 
     Other  4 (1.7) 
 
1  16VAs were excluded from the original sample, in view of them not ever having been used for dialysis 
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Table 3 Percentage of the most common complications according to each fistula type. 
 
 No Complications  Thrombosis  Stenosis 
Fistula Type N of Fistulas n %  n %  n % 
All  242 91 37.6  60 24.8  89 36.8 
BC 126 53 42.1  24 19.0  41 32.5 
 RC 39 15 38.5  8 20.5  13 33.3 
Graft 35 4 11.4  24 68.6  19 54.3 
TP 26 11 42.3  3 11.5  11 42.3 
SB 11 4 36.4  1 9.1  5 45.5 
UC 5 4 80.0  0 0.0  0 0.0 
N, number; BC, brachiocephalic; RC, radiocephalic; SB, snuffbox; TP, transposed; UC, ulnarcephalic. 
 
 
Table 4 Frequency of required interventions by fistula type 
 
  Number of Interventions 
Fistula Type Number of fistulas  None Thrombectomy Angioplasty 
Surgical 
Revision 
Brachiocephalic 126 60 6 38 39 
Radiocephalic 39 19 2 11 12 
Graft 35 6 25 20 12 
Transposed 26 12 0 10 5 
Snuffbox 11 5 0 5 1 
Ulnarcephalic 5 4 0 1 1 
Total 242 106 33 85 70 
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Figure 1 Kaplan-Meier survival curves for patency rates of total AVFs, showing primary  
  patency, assisted primary patency and secondary patency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No significant difference between having no 
complications (p=.507), or having thrombosis 
(p=.808), or stenosis (p=.513) was observed 
between the different AVF types (Table 3).  
However, a significant difference was 
observed between the rate of no 
complications (p<.001), thrombosis (p< .001) 
and stenosis (p=.020) for PTFE grafts when 
compared to the rest of the AVFs. 
The frequency of interventions carried out 
according to VA type are shown in Table 4. 
Over the analysis period, a total of 85 
angioplasties and 33 thrombectomies were 
carried out.  Surgical revision of the VA was 
required 70 times.  43.8% (n=106) of the VAs 
created required no intervention.  When 
looking at the various fistula types, only 16.6% 
of grafts required no intervention while 47.6% 
of brachiocepahlic, 48.7% of radiocephalic and, 
46.1% of transposed fistulae required no 
intervention.  When looking at the 
interventions carried out, we found that AVGs 
had an intervention rate of 0.27 per VA per 
year, when compared to AVFs with an 
intervention rate of 0.11 per VA per year.There 
was no significant difference between the 
different fistula types (p=.713) however there 
was significant difference in the rate of 
intervention between fistula and grafts 
(p<.001). 
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AVF Incidence 
Out of the 207 patients who had AVFs created 
since January 2012, only 26.1% (n=54) had AVF 
creation prior to initiation of HD. When 
calculating incident AVFs after May 2014, the 
end point of the local study by Caruana et al., 
the incident rate of AVFs was 28.6%, showing 
no significant difference (p=.584) and hence no 
significant improvement since the previous 
study.5 
Patency 
The primary patency rates for first-time AVFs 
were 58.7% (95% CI, 51.7%-65.7%) at 1 year 
and 48.1% (95% CI, 40.7%-55.5%) at 2 years 
respectively. The assisted primary rates were 
73.7% (95% CI, 67.4%-80.0%) at 1 year and 
67.6% (95% CI, 60.7%-74.5%) at 2 years., while 
the secondary patency rates were 76.4% (95% 
CI, 70.3%-82.5%) at 1 year and 70.8 %(95% CI, 
63.9%-77.7%) at 2 years. (Figure 1) 
The patency rates according to the different 
type of VA are shown in Table 5. There was no 
significant difference when comparing primary 
patency (p=.539), assisted primary patency 
(p=.634) or secondary patency rates (p=.783) 
for the different types of fistulas (Figure 2).  
The overall patency of AVGs was found to be 
lower at 17.1% (95%CI 4.6%-29.6%) primary 
patency, 17.1% (95%CI 4.6%-29.6%) assisted 
patency and 48.6% (95%CI 32.1%-65.1%)  
secondary patency.  Comparing to the patency 
of AVFs (Figure 3.), there was a statistically 
significant difference between primary 
patency (p<0.001), assisted primary patency 
(p<0.001) and secondary patency (p=.010)  
 
 
Table 5 Patency Rates According to Different Type of VA 
VA Type 
Overall 1 Year 2 Years 
P (%) AP (%) SP (%) P (%) AP (%) SP (%) P (%) AP (%) SP (%) 
Grafts 17.1 17.1 48.6 17.8 25.7 67.4 0 10.4 45.2 
All Fistulas 47.8 66.2 68.6 59.7 74.3 76.9 48.9 68.1 70.8 
BC 47.6 64.3 68.3 61 73.3 77.6 46.1 63.7 67.7 
RC 48.7 61.5 61.5 58.4 71.5 71.5 53 68.8 68.8 
SB 36.4 81.8 81.8 45.6 90.9 90.9 45.6 90.9 90.9 
TP 46.2 73.1 73.1 58.4 75.1 75.1 49.3 75.1 75.1 
UC 80 80 80 80 80 80 80 80 80 
VA, Vascular Access; P, primary patency; AP, assisted primary patency; SP, secondary patency; BC, 
brachiocephalic; RC, radiocephalic; SB, snuffbox; TP, transposed; UC, ulnarcephalic. 
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Figure 2 Kaplan-Meier survival curves for secondary patency rates, according to the different 
  types of fistulas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Kaplan-Meier survival curves comparing the secondary patency between AVFs and 
  AVGs 
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DISCUSSION 
The patency rates of AVFs fashioned in Malta 
over a 5 year period are similar to those 
reported in international literature.5-7  Al-Jaishi 
et al. who carried out a metaanalysis of 12,838 
fistulas over a 12 year period, concluded that 
one may expect  a primary patency rate of  
60±4% (1 year)  and  51±7% (2 years), and a 
secondary patency of  71±7% (1 year) and 
64±9% (2 years).6 These rates are very similar 
to patency rates achieved locally over the 
analysis period. In our study, the 1 year 
secondary patency rate of 76.4±6.1% is also 
similar to the 83.1% 1 year patency rate 
reported locally by Caruana et al. 5 
While McGrogan et al. had noted inferior 
primary and secondary patency rates of 
radiocephalic fistulas compared to 
brachiocephalic,8  we found no significant 
difference between primary or secondary 
patency rates between the two (p=.812 and 
p=.765 respectively). Similarly we found no 
significant difference when comparing all the 
different fistula types.   
There are varying patency rates reported when 
it comes to PTFE grafts. Our secondary 
patency rates of grafts are similar to those 
reported in studies by Ravari et al.9 and 
Disbrow et al. 10 When it comes to primary 
patency rates, while our local rates do 
compare to some studies eg. 19.5% (1 year)11, 
there are other studies which record 
considerably higher patency rates of 42-43% 
after a year.12-13 
With transposed fistulas we noted similar 
patency rates at 1 and 2 year intervals, when 
compared to non-transposed fistulas. This 
differs to the study by Choi et al. which noted 
superiority of transposed patency rates after 2 
years, despite similar rates after 1 year.14 
With regards to snuffbox fistulas, we reported 
very satisfactory assisted and secondary 
patency rates up to 2 years follow up. Our 1 
year secondary patency rates (90.9%)  are in 
keeping with the  93±4% quoted in literature 
however we lag behind in primary patency 
(45.6%)  when comparing to patency rates 
quoted from 65%-83%.15-16 Despite this, it 
should be noted that our snuffbox fistula 
sample was relatively small (5.3%, n=11), and 
may therefore not be thoroughly 
representative. Snuffbox fistulas have the 
advantage of easier anastomosis due to closer 
proximity between artery and vein, as well as a 
reduced risk of steal in view of narrower artery 
caliber, which makes them an attractive option 
for fistula creation.15 
Incidence of complications in fistulae were in 
keeping with reported incidence published by 
Stolic et al, with thrombosis 17-25% and 
stenosis 14-42%.17 Although no difference in 
complication rates were noted between fistula 
types locally, it must be said that the 
ulnarcephalic and snuffbox fistula samples 
were small, and may not be fully 
representative.  We did note that 43.8% of 
AVFs and AVGs created required some sort of 
intervention, be it surgical or endovascular. 
This highlights the high demand of stress 
placed on, not only the health service, but also 
on the physical and mental wellbeing of 
already vulnerable patients.  
In 2006, the National Kidney Foundation (NFK) 
through the  Kidney Disease Outcomes Quality 
Initiative (KDOQI) released updated guidelines 
which recommends incident fistula rates of 
50% and at least 40% prevalent rates in 
patients undergoing haemodialysis. The 
Centers for Medicare & Medicaid Services 
(CMS) implemented a Fistula First 
Breakthrough Initiative (FFBI) in an attempt to 
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achieve these rates. In 2009, the target 
incidence rate was increase to 65%. In the 
study carried out by Caruana et al, which 
reviewed fistulae in Malta from October 2012 
to May 2014 showed that only 25% of people 
had a functioning fistula before 
haemodialysis.5 This is in keeping with our 
findings of 26.1%  Even when analyzing our 
data from May 2014 onwards, the rate showed 
no significant improvement since the last local 
study carried out indicating that 
recommended targets are far from being 
reached. 
 When comparing this to countries across the 
world, we find that Malta lags behind the 
European average (66%) and most of the 
major countries such as Germany (72%), Japan 
(69%), Italy (61%), Spain (64%) and UK (37%).  
Our fistula incidence rates are comparable to 
Belgium (26%) and Canada (26%) while 
surpassing those of the USA (16%).18 While the 
FFBI initiative had brought on a welcome 
improvement in fistula rates, it also led to 
increase in AVF failure rates and procedures 
required to salvage them.  
In conclusion, we found that in Malta the  AVF 
incidence lags behind the European average, 
but patency rates are comparable with most 
other countries. Efforts should be made for 
earlier referral to vascular surgeons and close 
liaison with the attending nephrologist to 
ensure the best possible patient-centered 
care.  
SUMMARY BOX 
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